1. Introduction {#sec1}
===============

Hyperuricemia is an old topic in the field of metabolic disorders and a common fundamental disease for gout, renal dysfunction, and other cardiovascular diseases \[[@B1]\]. The disease is attracting more and more eyes of biologists and medical scientists because of the high morbidity and economic burden \[[@B2]\]. Hyperuricemia has a male dominance and can be diagnosed by the level of serum uric acid (SUA) above 420 *μ*M (70 *μ*g/ml) \[[@B2]\].

The direction cause of hyperuricemia is the accumulation of uric acid in the body. Uric acid is the final product of purine nucleoside metabolism, synthesized by xanthine dehydrogenase (Xdh) in humans though it can be further transformed into allantoin by uricase (Uox) in other animals except some birds and reptiles \[[@B3]\]. Uric acid can be found in cells, tissues, and organs, and the level of uric acid is different from organ to organ. It was supposed that the liver was the most important organ to generate uric acid \[[@B4], [@B5]\], but strangely, not the organ with the highest level of uric acid \[[@B6]\]. The dominant source of uric acid (about 2/3 or more) is generated from endogenous purines, and the rest from the exogenous \[[@B4]\]. It is certain that two-thirds or more uric acid is excreted through the kidney, and the rest through feces \[[@B4]\]. Although there were systematic data about the distribution of uric acid in rats \[[@B6]\], the significance of uric acid in different organs was poorly understood.

It was believed that uric acid was a metabolic waste of nucleosides just like urea for proteins, since there was almost no functional disturbance if the level of serum uric acid was lowered deeply by Uox, say rasburicase \[[@B7]\]. However, some reports declared that uric acid played roles in some physiologic functions and should not be eliminated thoroughly \[[@B8], [@B9]\]. Due to its antioxidant activity, uric acid was thought to protect neuronal cells, consequently facilitating brain evolution or development \[[@B8], [@B10], [@B11]\], and also play a role in maintaining the blood pressure \[[@B8]\]. However, the antioxidant activity of uric acid is not powerful than either hydrophilic vitamin C or hydrophobic vitamin E according to its chemical structure. The effects resulted from the antioxidant activity can be easily substituted by intake of the two vitamins \[[@B12], [@B13]\] and other foods containing reducing chemicals \[[@B14]\]. Therefore, its antioxidant activity is not as important as previously supposed. So, the function of uric acid in the organs is still unclear. In the present study, uric acid in different rat organs and their mRNA expression level would be determined, and the relationship between them would be analyzed to find its function.

2. Materials and Methods {#sec2}
========================

2.1. Materials {#sec2.1}
--------------

Male Sprague-Dawley (SD) rats aged 2 months and weighing 180-220 g were obtained from Kunming Medical University, Kunming, China. Rats were housed at 22°C temperature, at 45-55% humidity-controlled conditions, and under natural light. Clinical data were collected from the Third Affiliated Hospital, Kunming Medical University. This project was approved by the Experimental Animal Committee of Kunming Medical University and the Medical Ethics Committee of Kunming Medical University.

Uric acid was purchased from Tokyo Into Industrial Co. Ltd. (Tokyo, Japan). Uric acid assay kits of the phosphotungstic acid method and protein assay kits of the BCA (bicinchoninic acid) method were purchased from Nanjing Jiancheng Bioengineering Institute (Nanjing, China). TRIzol Plus RNA Purification Kit was purchased from Invitrogen (Carlsbad, CA, USA). Ultrapure water was obtained from the Milli-Q water purification system manufactured by the EMD Millipore Group (Darmstadt, Germany). The NanoDrop ND-1000 spectrophotometer was manufactured by PeqLab, Erlangen, Germany. The multimicroplate reader of Infinite 200 PRO was manufactured by Tecan Group (Männedorf, Switzerland). Other instruments or reagents used in the present study were made in China.

2.2. Animal Treatment and Uric Acid Assay {#sec2.2}
-----------------------------------------

Animal treatment followed the methods of Yun et al. \[[@B6]\]. Briefly, SD rats were fasted for 36 h before sacrificing. The rats were intraperitoneally anaesthetized with urethane (1.0 g/kg). The abdomen of the rat was opened, blood samples were drawn via the abdominal aorta, and organs including the liver, spleen, lung, bladder, pancreas, kidney, testicle, brain, heart, ectogluteus, duodenum (5 cm), and the last 5 cm of the ileum were harvested. The intestinal tract was opened and the inner wall was cleaned with a cotton swab and was rinsed with 1 ml normal saline twice. The sample of the organs was frozen at -40°C for use or homogenized on ice immediately.

The concentration of uric acid (*μ*g/ml) in the serum samples and the supernatant of the tissue homogenate was assayed with uric acid assay kits according to the standard operation procedure (SOP) provided by the manufacturer. The protein in all the samples was assayed with protein assay kits.

2.3. mRNA Quantitative Sequencing {#sec2.3}
---------------------------------

After the organs of the rats including the brain, kidney, lung, liver, heart, stomach, duodenum, and terminal ileum were harvested, about 200 mg tissue was sampled. The sample was frozen with liquid nitrogen and ground to powder. The total RNA in the powder was extracted and purified by TRIzol Plus RNA Purification Kit. RNA quantity and quality were measured by the NanoDrop ND-1000 spectrophotometer. RNA integrity was assessed by standard denaturing agarose gel electrophoresis \[[@B15], [@B16]\].

Double-stranded cDNA (ds-cDNA) was synthesized from the total RNA using an Invitrogen SuperScript ds-cDNA synthesis kit in the presence of 100 pmol/l oligo dT primers. The cDNA was sequenced by Sangon Biotech (Shanghai, China). The expected value of FPKM (fragments per kilobase of transcript sequence per million base pairs sequenced) was used for expression normalization \[[@B17], [@B18]\]. The relationship analysis of the FPKM value of a gene between different organs and the pathway analysis associated with related genes \[[@B15]\] were also made by Sangon Biotech.

2.4. Clinical Data {#sec2.4}
------------------

Clinical data including 203 cases of breast cancer (aged 24-80) and 100 cases of benign breast tumor (aged 28-61) were provided by the Third Affiliated Hospital, Kunming Medical University. All the cases were from female patients and confirmed by pathological diagnosis. Cases with severe hepatic and renal dysfunction or complicated with other tumors were excluded. SUA was assayed with uric acid assay kits of uricase methods, and the Ki67 antigen in cancer tissue was assayed with ELISA kits by the clinical laboratory of the hospital.

2.5. Statistical Analysis {#sec2.5}
-------------------------

Values were expressed as mean ± SD (standard deviation). Student\'s *t*-test was performed to compare means between different groups. Bivariate correlations of Pearson\'s method (two-tailed) were performed to find the relationship between the level of uric acid and the FPKM values of the organs. Statistical significance was accepted at *P* \< 0.05.

3. Results {#sec3}
==========

3.1. Distribution of Uric Acid in Different Organs in Normal Rats {#sec3.1}
-----------------------------------------------------------------

The distribution of uric acid in different organs was showed in [Figure 1](#fig1){ref-type="fig"}. The organ with the highest level of uric acid was the duodenum, then the ileum and liver, belonging to the alimentary system \[[@B6]\] and suggested that the alimentary system was a dominant place for uric acid distribution.

In neonatal rats (less than 2 hours after birth), uric acid in the intestinal tract was similar to that in normal rats. However, uric acid in the heart and liver, unlike that in normal rats, was very low, different from that in normal rats ([Figure 2](#fig2){ref-type="fig"}).

3.2. Relationship between the Level of Uric Acid and Pathways in Different Organs {#sec3.2}
---------------------------------------------------------------------------------

The results of mRNA quantitative sequencing showed that there were 32,662 mRNAs sequenced in every organ. The correlation between uric acid and the FPKM value was performed to find the relationship. Since mRNAs with multiple zero values of FPKM were unsuitable to perform correlation analysis, only 7604 mRNAs were taken into account, and 1937 mRNAs with a *P* value below 0.05 were selected. The pathways they could be involved in were also analyzed; 56 pathways with significance (*P* \< 0.05) were screened out ([Table S1](#supplementary-material-1){ref-type="supplementary-material"}), and the top 20 were showed in [Table 1](#tab1){ref-type="table"}. Most pathways were associated with purine or nucleoside metabolism, cellular metabolism, cell cycles, and cell death.

3.3. Relationship between the Level of Uric Acid and Gene Expression in Different Organs {#sec3.3}
----------------------------------------------------------------------------------------

Uric acid is directly produced from xanthine by Xdh, while Ada (adenosine deaminase) is an important assistant to the kinase \[[@B19]\]. Their expression levels were both upregulated in organs where uric acid was high \[[@B6], [@B19]\]. However, as for Uox, there was no significant correlation between its expression level and uric acid ([Table 2](#tab2){ref-type="table"}).

ATP is generated mainly by the Krebs cycle in the mitochondria and is a key fuel to drive cellular function. ATP is a polar molecule with negative charges, unlikely provided by neighbor cells or cells faraway. The increase of ATP will be associated with the upregulation of ATP synthase. However, there was no significant correlation between the level of uric acid and ATP synthase expression, though ATPases were upregulated in the brain and heart (both of Atpaf1 and Atpaf2, [Table 3](#tab3){ref-type="table"}). On the other hand, Na^+^-K^+^-ATPase, a key enzyme concluding 8 subunits to maintain cellular polarization, is highly associated with cell viability; only one of the subunits was merely, but negatively, correlated with the level of uric acid ([Table 3](#tab3){ref-type="table"}).

The main way of physiological cell death is regulated cell death (RCD); among which, caspase 3 (Casp3) is an executor to directly cause cell death \[[@B20], [@B21]\]. Of course, there was a good correlation between the level of uric acid and the enzyme ([Table 3](#tab3){ref-type="table"}).

MKi67 is a cell cycle and tumor growth marker presenting only in the nuclei of cycling cells and upregulated in cycling cells \[[@B22], [@B23]\]. In [Table 3](#tab3){ref-type="table"}, there was also a good correlation between the expression level of MKi67 and the level of uric acid, though the correlation coefficient (*R* = 0.7768) was smaller than that of Casp3 (*R* = 0.9045).

3.4. SUA in Breast Cancer {#sec3.4}
-------------------------

[Figure 3(a)](#fig3){ref-type="fig"} shows that the level of SUA in patients with breast cancer was higher than that in patients with benign breast tumor. Ki67 is a factor for tumor growth in human \[[@B22], [@B23]\]. However, there was no correlation between the level of SUA and Ki67 ([Figure S1](#supplementary-material-1){ref-type="supplementary-material"}) in the patients with breast cancer. The patients that suffered with breast cancer were treated with chemotherapeutics, and when a treatment course was ended, the level of SUA increased to some extent ([Figure 3(b)](#fig3){ref-type="fig"}).

4. Discussion {#sec4}
=============

The function of uric acid in the body was a hot topic. Some studies believe that uric acid might play some roles in physiological activities, like to protect neurons from oxidative damage and to maintain blood pressure \[[@B8], [@B24]\]. However, there was an opposite opinion that regarded the metabolite just as a waste \[[@B25], [@B26]\].

4.1. Uric Acid Synthesized from Local Degraded Nucleosides {#sec4.1}
----------------------------------------------------------

In all the organs the present study involved, the expression level of Xdh was highly correlated with the level of uric acid ([Table 1](#tab1){ref-type="table"}), and so was Ada, an enzyme indirectly associated with uric acid synthesis. The results suggested that uric acid was locally synthesized from the degraded nucleosides. As for the urate destroyer, Uox was highly expressed only in the liver ([Table 1](#tab1){ref-type="table"}). The results suggested that uric acid was almost a final product of purines in the extrahepatic organs in rats and can be transported to the liver for further degradation.

4.2. Uric Acid Unlikely to Play an Important Role to Protect Neurons or Maintain Blood Pressure {#sec4.2}
-----------------------------------------------------------------------------------------------

Neurons predominantly distribute in the brain. According to the known understandings, the rat brain is about 0.4 percent of the body weight but consumes 10-20 percent of the cardiac output. Because the brain has to consume massive oxygen to maintain its complicated function, genes directly associated with ATP synthesis should be expressed at a high level. Unsurprisingly, the expression level of the genes was overall higher than that in other organs ([Table 3](#tab3){ref-type="table"}). Theoretically, in the process of biological oxidation, many oxygen radicals will be also generated and then could damage neurons. Based on knowledge, some reports even deduced that uric acid played a role in neuroprotection \[[@B8]\] and Uox deficiency, a factor facilitating uric acid increase, was considered as a big step for human brain evolution and development \[[@B10], [@B11]\]. However, Uox deficiency is a common phenomenon in lower animals like birds and reptiles \[[@B3]\]. On the other hand, the heart is the second organ with a high level of energy metabolism. Unfortunately, the level of uric acid in the organ was also low ([Figure 1](#fig1){ref-type="fig"}). Similarly, the duodenum was the organ with the highest level of uric acid, but there were no reports that believed that the intestinal tract was an organ with high energy consumption. Therefore, the present study proved that uric acid was unlikely to play an important role in protecting neurons by quenching oxygen radicals, at least in a physiological state, though it is a real reductive substance.

Epidemic data suggested that hyperuricemia highly correlated with hypertension \[[@B27]\]. However, the relationship between uric acid and blood pressure was concomitant rather than causal. Both diseases are age-dependent, and there were rare concrete experimental evidences supporting the hypothesis that hyperuricemia could result in hypertension and vice versa. Further, there were almost no clues in uric acid-lowering drugs associated with blood pressure lowering \[[@B7]\]. From the analysis, uric acid was unlikely to play an important role in maintaining blood pressure either.

4.3. Uric Acid Was an Indicator for Cell Death {#sec4.3}
----------------------------------------------

Uric acid was a metabolite from purines, while purines in the body came mainly from endogenously degraded nucleosides and partly from diet. Nucleosides might come from used DNA or RNA. A cell in a vigorous metabolism state needs many mRNAs to synthesize protein, and the used mRNAs will be degraded. Then, a part of them will be recycled to synthesize new mRNAs and a part will be transformed to uric acid. However, when a cell dies, the whole nucleus where abundant DNAs are located, along with the RNA in the cytoplasm, could be degraded, and many of which would be transformed to uric acid rather than recycled. Since the nucleus contains even more amount of nucleotides than the cytoplasm, a dead cell would result in more uric acid. By contrast with the yield of nucleosides from the nucleus, the yield of nucleosides from the cytoplasm meant nothing. So, there was no significant correlation between uric acid and energy metabolism. RCD is the main physiological way of cell death, and Casp3 is the main executor for RCD pathways \[[@B21]\]. Since uric acid in an organ was highly correlated to the expression level of the gene ([Table 3](#tab3){ref-type="table"}), the results supported that uric acid was mainly resulted from dead cells. However, in a physiological state, dead cells are often replaced by regenerated cells, a process which is associated with Ki67 activation, an important nuclear protein \[[@B22], [@B23]\]. Results in [Table 3](#tab3){ref-type="table"} supported the deduction but with a smaller *R* value than Casp3. Since cell proliferation in the heart and liver was the main process in neonatal rats, there could be almost no cell death in the two neonatal organs ([Figure 2](#fig2){ref-type="fig"}). However, the intestinal tract both in neonatal rats and normal rats might be associated with many cell deaths and regeneration to remodel itself (Figures [1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}).

In the clinic, advanced cancer growth often couples with tumor cell death, and so does breast cancer. The degraded nucleosides in the dead tumor cells would be transformed into uric acid and caused an SUA increase ([Figure 3(a)](#fig3){ref-type="fig"}). Surprisingly, there was no significant correlation between Ki67 and SUA in patients with breast cancer but with a very slight tendency (*P* \> 0.05, [Figure S1](#supplementary-material-1){ref-type="supplementary-material"}). This phenomenon was different from that in normal rats. The reason might be associated with cell death inducing cell regeneration in normal rats, while tumor cell proliferation resulting in cell necrosis in patients with cancer. When breast cancer is treated with chemotherapeutics, many tumor cells would be killed. The nucleosides in the cells would be transformed into uric acid and caused an SUA increase ([Figure 3(b)](#fig3){ref-type="fig"}). Indeed, an SUA increase, including hyperuricemia and even gout, was widely regarded as an important marker for tumor lysis syndrome (TLS) \[[@B7], [@B28]\].

5. Conclusion {#sec5}
=============

In summary, the dead cell was the main source for degraded nucleosides, and purines from the nucleosides would be transformed into uric acid locally. The uric acid would be transported to the blood and eventually would be excreted through the kidney or intestinal tract or deposited locally to cause tissue damage. The level of uric acid can be used as a reliable, though not sensitive sometimes, marker to evaluate cell death.

This work was supported by the Foundation for Scientific Research provided by the Yunnan Province Education Department (2018JS153) and by the National Natural Science Foundation of China (81860162).

Data Availability
=================

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest
=====================

The authors declare that they have no conflicts of interest.

Authors\' Contributions
=======================

Dequan Liu and Yu Yun contributed equally to this work.

Supplementary Materials {#supplementary-material-1}
=======================

###### 

Table S1: pathways with significance associated with the level of uric acid in different organs (*n* = 3). Figure S1: the relationship between SUA and Ki67 in patients with breast cancer (*n* = 203).

###### 

Click here for additional data file.

![Distribution of uric acid in male rat\'s organs (mean + SD, *n* = 10, data cited from our previous study \[[@B6]\]). Ileum: the last 5 cm of the ileum; skeletal muscle: the ectogluteus.](DM2019-4081962.001){#fig1}

![Distribution of uric acid in neonatal rats (mean + SD, *n* = 3).](DM2019-4081962.002){#fig2}

![Serum uric acid (SUA) in patients with breast tumors (mean ± SD). The level of SUA before treatment in patients with malignant breast tumor (breast cancer) was higher than that in patients with benign breast tumor. (a) Benign group (*n* = 100) and malignant group (*n* = 203), *P* ≤ 0.001, independent samples *t*-test. When patients with breast cancer are treated with chemotherapeutics, the level of SUA further increased. (b) *n* = 203, *P* ≤ 0.001, paired *t*-test.](DM2019-4081962.003){#fig3}

###### 

Top 20 pathways with significance could be associated with the level of uric acid in different organs.

  ID        Description                                       Significant   Annotated   *P* value   *Q* value   Positive num.   Negative num.
  --------- ------------------------------------------------- ------------- ----------- ----------- ----------- --------------- ---------------
  ko03010   Ribosome                                          184/1937      288/7604    1.26E-44    3.37E-42    172             12
  ko04141   Protein processing in the endoplasmic reticulum   89/1937       172/7604    8.09E-14    1.09E-11    62              27
  ko00240   Pyrimidine metabolism                             50/1937       106/7604    9.93E-07    8.89E-05    36              14
  ko04975   Fat digestion and absorption                      24/1937       39/7604     1.99E-06    0.000134    21              3
  ko00520   Amino sugar and nucleotide sugar metabolism       27/1937       49/7604     8.96E-06    0.000481    19              8
  ko05110   Vibrio cholerae infection                         28/1937       52/7604     1.11E-05    0.000494    14              14
  ko00230   Purine metabolism                                 68/1937       170/7604    1.88E-05    0.000721    38              30
  ko00480   Glutathione metabolism                            28/1937       54/7604     2.80E-05    0.000941    21              7
  ko00983   Drug metabolism (other enzymes)                   22/1937       39/7604     3.73E-05    0.001011    19              3
  ko03460   Fanconi anemia pathway                            27/1937       52/7604     3.77E-05    0.001011    18              9
  ko03008   Ribosome biogenesis in eukaryotes                 37/1937       81/7604     5.99E-05    0.001462    25              12
  ko00620   Pyruvate metabolism                               23/1937       43/7604     7.72E-05    0.001727    10              13
  ko00330   Arginine and proline metabolism                   28/1937       59/7604     0.000209    0.004278    17              11
  ko00500   Starch and sucrose metabolism                     21/1937       40/7604     0.000223    0.004278    12              9
  ko03030   DNA replication                                   20/1937       38/7604     0.000301    0.00538     16              4
  ko00900   Terpenoid backbone biosynthesis                   14/1937       23/7604     0.000342    0.005742    10              4
  ko00561   Glycerolipid metabolism                           26/1937       56/7604     0.000534    0.008435    19              7
  ko04972   Pancreatic secretion                              40/1937       98/7604     0.000587    0.008748    33              7
  ko04113   Meiosis (yeast)                                   26/1937       59/7604     0.001403    0.019819    19              7
  ko04111   Cell cycle (yeast)                                29/1937       70/7604     0.002443    0.032791    24              5
  ko00970   Aminoacyl-tRNA biosynthesis                       21/1937       47/7604     0.003207    0.03985     12              9
  ko00510   N-Glycan biosynthesis                             22/1937       50/7604     0.003266    0.03985     19              3
  ko02020   Two-component system                              10/1937       17/7604     0.003564    0.041593    6               4
  ko04110   Cell cycle                                        45/1937       123/7604    0.003905    0.043679    42              3
  ko04210   Apoptosis                                         33/1937       85/7604     0.004440    0.045337    21              12
  ko03440   Homologous recombination                          14/1937       28/7604     0.004476    0.045337    10              4
  ko00100   Steroid biosynthesis                              11/1937       20/7604     0.004560    0.045337    11              0
  ko04910   Insulin signaling pathway                         48/1937       134/7604    0.004738    0.045421    19              29
  ko00564   Glycerophospholipid metabolism                    35/1937       92/7604     0.005061    0.046841    23              12
  ko03060   Protein export                                    12/1937       23/7604     0.005410    0.048403    8               4

###### 

FPKM of genes mainly associated with urate metabolism and its correlation with the level of uric acid in different rat organs (mean ± SD, *n* = 3).

  Gene   Brain         Kidney         Lung            Liver            Heart           Stomach        Duodenum           Terminal ileum   *R*      *P*
  ------ ------------- -------------- --------------- ---------------- --------------- -------------- ------------------ ---------------- -------- -----------
  Xdh    2.57 ± 0.19   35.45 ± 3.79   66.10 ± 11.01   32.08 ± 1.73     26.76 ± 13.90   18.94 ± 5.88   281.88 ± 15.59     89.74 ± 14.30    0.9279   6.776E-11
  Ada    1.62 ± 0.85   9.59 ± 2.00    19.59 ± 4.84    3.15 ± 0.61      7.83 ± 0.17     4.68 ± 1.10    1471.86 ± 703.35   225.33 ± 75.40   0.8874   3.79E-08
  Uox    0.14 ± 0.15   0.03 ± 0.06    0.09 ± 0.08     384.58 ± 79.50   0 ± 0           0.08 ± 0.07    0.02 ± 0.03        0.084 ± 0.07     0.1128   0.5999

###### 

FPKM of genes mainly associated with cell proliferation, apoptosis, and viability and its correlation with the level of uric acid in different rat organs (mean ± SD, *n* = 3).

  Gene     Stomach           Kidney             Brain              Lung             Liver           Heart            Duodenum           Terminal ileum     *R*       *P*
  -------- ----------------- ------------------ ------------------ ---------------- --------------- ---------------- ------------------ ------------------ --------- -----------
  Atpaf1   11.95 ± 3.43      13.11 ± 0.80       16.36 ± 2.17       6.48 ± 1.23      6.93 ± 1.99     15.12 ± 1.65     12.14 ± 2.04       10.72 ± 0.78       -0.3118   0.0972
  Atpaf2   15.70 ± 1.12      16.74 ± 0.49       20.09 ± 0.87       10.76 ± 1.66     8.25 ± 0.59     23.01 ± 1.34     11.06 ± 2.69       11.14 ± 0.70       -0.6739   0.4541
  Atp1a1   159.40 ± 49.43    1164.81 ± 7.36     448.52 ± 159.18    162.10 ± 12.58   126.8 ± 10.27   195.50 ± 69.00   930.40 ± 133.72    849.92 ± 95.97     0.3806    0.0665
  Atp1a2   7.61 ± 2.98       4.78 ± 0.79        311.30 ± 57.23     14.52 ± 1.51     0.40 ± 0.41     63.22 ± 9.10     1.44 ± 0.23        7.37 ± 3.94        -0.4183   0.0419
  Atp1a3   0.08 ± 0.06       0.10 ± 0.07        755.68 ± 95.52     3.25 ± 0.31      0.05 ± 0.07     1.48 ± 1.77      0.42 ± 0.15        0.48 ± 0.21        -0.3382   0.1060
  Atp1a4   0 ± 0             0.92 ± 0.39        0.01 ± 0.01        0.05 ± 0.02      0 ± 0           0.04 ± 0.02      0 ± 0              0.04 ± 0.02        -0.2521   0.2347
  Atp1b1   994.36 ± 127.15   2309.92 ± 166.22   1692.65 ± 175.76   101.26 ± 6.09    22.01 ± 6.89    307.94 ± 43.10   1345.89 ± 208.94   1265.77 ± 110.33   -0.0182   0.9329
  Atp1b2   13.91 ± 2.54      6.28 ± 0.30        358.56 ± 211.59    3.79 ± 0.37      0.45 ± 0.02     12.90 ± 2.95     2.93 ± 0.68        4.27 ± 0.30        -0.3207   0.1265
  Atp1b3   54.20 ± 5.53      63.09 ± 2.46       97.00 ± 16.34      169.85 ± 6.17    21.31 ± 1.16    48.63 ± 4.95     46.75 ± 4.69       40.10 ± 7.29       -0.2481   0.2425
  Atp1b4   0 ± 0             0.01 ± 0.02        0 ± 0              1.10 ± 0.05      0 ± 0           2.73 ± 4.63      0.01 ± 0.01        0.01 ± 0.01        -0.2032   0.3410
  Casp3    16.19 ± 4.95      4.73 ± 0.55        11.00 ± 1.25       15.79 ± 0.60     12.95 ± 1.30    4.96 ± 0.71      130.27 ± 27.41     41.27 ± 6.77       0.9045    1.325E-09
  MKi67    5.29 ± 0.75       2.02 ± 0.41        0.50 ± 0.06        7.23 ± 2.60      1.74 ± 0.41     1.64 ± 1.11      12.99 ± 3.88       12.94 ± 2.19       0.7768    8.067E-06

[^1]: Academic Editor: Olav Lapaire
